Dianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $42.00 at Wedbush

Dianthus Therapeutics (NASDAQ:DNTH) had its price objective increased by Wedbush from $34.00 to $42.00 in a research note published on Thursday morning,Benzinga reports. Wedbush currently has an outperform rating on the stock.

Several other analysts have also recently commented on the stock. Robert W. Baird lowered their target price on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an “outperform” rating for the company in a research note on Tuesday, May 13th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research note on Tuesday, May 13th. Finally, William Blair initiated coverage on shares of Dianthus Therapeutics in a research note on Wednesday, July 2nd. They issued an “outperform” rating for the company. Seven equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $54.00.

Dianthus Therapeutics Price Performance

Shares of DNTH opened at $23.65 on Thursday. The firm has a 50 day simple moving average of $19.82 and a 200-day simple moving average of $20.03. Dianthus Therapeutics has a 1-year low of $13.36 and a 1-year high of $32.27. The stock has a market cap of $761.29 million, a price-to-earnings ratio of -7.28 and a beta of 1.43.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). The business had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $0.87 million. Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%. On average, equities analysts expect that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Institutional Trading of Dianthus Therapeutics

Several institutional investors have recently made changes to their positions in DNTH. JPMorgan Chase & Co. grew its stake in shares of Dianthus Therapeutics by 14.0% during the 4th quarter. JPMorgan Chase & Co. now owns 12,129 shares of the company’s stock valued at $264,000 after buying an additional 1,490 shares during the period. Invesco Ltd. grew its stake in shares of Dianthus Therapeutics by 7.4% during the 4th quarter. Invesco Ltd. now owns 11,521 shares of the company’s stock valued at $251,000 after buying an additional 790 shares during the period. Legal & General Group Plc grew its stake in shares of Dianthus Therapeutics by 23.7% during the 4th quarter. Legal & General Group Plc now owns 12,319 shares of the company’s stock valued at $269,000 after buying an additional 2,363 shares during the period. Barclays PLC grew its stake in shares of Dianthus Therapeutics by 2.6% during the 4th quarter. Barclays PLC now owns 42,766 shares of the company’s stock valued at $933,000 after buying an additional 1,082 shares during the period. Finally, MetLife Investment Management LLC grew its stake in shares of Dianthus Therapeutics by 3.1% during the 4th quarter. MetLife Investment Management LLC now owns 14,372 shares of the company’s stock valued at $313,000 after buying an additional 433 shares during the period. 47.53% of the stock is owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.